VivoSeq
Other

Carotid Endarterectomy

0

Pipeline Programs

0

Active Trials

2

Companies Involved

Carotid Endarterectomy is an early-stage landscape with 0 programs across 2 companies. The most active players are Tallikut Pharmaceuticals, Inc., GSK.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

14/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

14

clinical trials

Completed10 · 71%
Unknown status2 · 14%
Withdrawn1 · 7%
Terminated1 · 7%

Trial Activity

14 trials

Effect of Blood Pressure on rSO2 in Carotid Endarterectomy (CEA)
Unknown status··N/A·NCT01451294·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)